PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of
talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy
(PRRT) in patients with metastatic pancreatic neuroendocrine tumour (NET).